Tovorafenib

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameTovorafenib
Drug Alias NameOJEMDA™MLN-2480BIIB-024TAK-580AMG-2112819 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsB-raf V600E inhibitorsC-Raf kinase inhibitors
TargetsSerine/threonine-protein kinase B-rafB-raf V600EC-Raf kinase
Therapy Area/IndicationsHigh-Grade GliomaLow-grade GliomaSolid tumours +[17] 
Global Approved IndicationsGlioma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/04/23
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSunesis Pharmaceuticals IncBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteIpsenXoma Corp +[8] 
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsHigh-Grade GliomaLow-grade GliomaSolid tumours +[8] 
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG